Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

USA - NASDAQ:DNLI - US24823R1059 - Common Stock

13.16 USD
-1.03 (-7.26%)
Last: 9/15/2025, 8:00:01 PM
13.2 USD
+0.04 (+0.3%)
After Hours: 9/15/2025, 8:00:01 PM
Fundamental Rating

2

Overall DNLI gets a fundamental rating of 2 out of 10. We evaluated DNLI against 540 industry peers in the Biotechnology industry. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability. DNLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DNLI has reported negative net income.
DNLI had a negative operating cash flow in the past year.
In the past 5 years DNLI reported 4 times negative net income.
DNLI had negative operating cash flow in 4 of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

With a decent Return On Assets value of -30.77%, DNLI is doing good in the industry, outperforming 65.74% of the companies in the same industry.
With a decent Return On Equity value of -34.38%, DNLI is doing good in the industry, outperforming 75.37% of the companies in the same industry.
Industry RankSector Rank
ROA -30.77%
ROE -34.38%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DNLI has been increased compared to 1 year ago.
The number of shares outstanding for DNLI has been increased compared to 5 years ago.
Compared to 1 year ago, DNLI has a worse debt to assets ratio.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

DNLI has an Altman-Z score of 5.88. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DNLI (5.88) is better than 78.15% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DNLI is not too dependend on debt financing.
DNLI has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.88
ROIC/WACCN/A
WACC9.58%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 8.46 indicates that DNLI has no problem at all paying its short term obligations.
DNLI has a better Current ratio (8.46) than 75.56% of its industry peers.
A Quick Ratio of 8.46 indicates that DNLI has no problem at all paying its short term obligations.
DNLI's Quick ratio of 8.46 is fine compared to the rest of the industry. DNLI outperforms 75.56% of its industry peers.
Industry RankSector Rank
Current Ratio 8.46
Quick Ratio 8.46
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.08% over the past year.
The Revenue for DNLI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.03%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DNLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.27% on average per year.
Based on estimates for the next years, DNLI will show a very strong growth in Revenue. The Revenue will grow by 138.30% on average per year.
EPS Next Y-15.76%
EPS Next 2Y-6.35%
EPS Next 3Y1.02%
EPS Next 5Y13.27%
Revenue Next Year-99.18%
Revenue Next 2Y180.11%
Revenue Next 3Y183.22%
Revenue Next 5Y138.3%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
Also next year DNLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.35%
EPS Next 3Y1.02%

More info and screens

0

5. Dividend

5.1 Amount

DNLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (9/15/2025, 8:00:01 PM)

After market: 13.2 +0.04 (+0.3%)

13.16

-1.03 (-7.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-04 2025-11-04
Inst Owners95.59%
Inst Owner Change-3.9%
Ins Owners4.85%
Ins Owner Change0.58%
Market Cap1.92B
Analysts88
Price Target32.79 (149.16%)
Short Float %10.22%
Short Ratio8.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-0.5%
Max EPS beat(2)18.24%
EPS beat(4)2
Avg EPS beat(4)6.14%
Min EPS beat(4)-8.8%
Max EPS beat(4)18.24%
EPS beat(8)4
Avg EPS beat(8)38.34%
EPS beat(12)6
Avg EPS beat(12)26.96%
EPS beat(16)6
Avg EPS beat(16)9.31%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)184.22%
Revenue beat(12)4
Avg Revenue beat(12)121.08%
Revenue beat(16)4
Avg Revenue beat(16)75.15%
PT rev (1m)-2.39%
PT rev (3m)-2.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)-1.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-99.68%
Revenue NY rev (3m)-99.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-3.02
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS8.41
TBVpS8.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.77%
ROE -34.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.46
Quick Ratio 8.46
Altman-Z 5.88
F-Score1
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)141.82%
Cap/Depr(5y)112.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.03%
EPS Next Y-15.76%
EPS Next 2Y-6.35%
EPS Next 3Y1.02%
EPS Next 5Y13.27%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.18%
Revenue Next 2Y180.11%
Revenue Next 3Y183.22%
Revenue Next 5Y138.3%
EBIT growth 1Y-155.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.96%
EBIT Next 3Y5.02%
EBIT Next 5Y18.15%
FCF growth 1Y1.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.88%
OCF growth 3YN/A
OCF growth 5YN/A